The interplay of physical activity and smoking with metabolic syndrome and its components in the STEPS survey
April 12, 2025 / Metabolic syndrome / Physical inactivity / Smoking risk / Abdominal obesity / Cardiometabolic health
Low physical activity poses a greater risk for metabolic syndrome (MetS) than smoking. Combined, they significantly elevate the odds of MetS, abdominal obesity, and high triglycerides, reinforcing the need for targeted prevention strategies.
Prevalence of CKM Among US Adults Increased Over Time
April 12, 2025 / CKM syndrome / Obesity risk / Chronic kidney disease / Cardiovascular disease / Metabolic health
CKM syndrome prevalence in U.S. adults rose from 76.5% to 82.2% between 2001–2020, driven largely by increased stage 1 CKM. Early detection of obesity and metabolic risks offers critical prevention opportunities for CKD and cardiovascular disease.
Can psychedelics break compulsive eating habits in obesity?
April 10, 2025 / obesity treatment / compulsive eating / psychedelic therapy / food addiction / cognitive flexibility
Psychedelics may offer therapeutic potential for compulsive overeating in obesity by enhancing cognitive flexibility and altering stimulus-reward associations. While promising mechanisms exist, human trials in obese populations are lacking, and more clinical evidence is needed.
A type of Mediterranean diet may support weight loss and bone health
April 12, 2025 / Mediterranean diet / bone health obesity / metabolic syndrome women / osteoporosis prevention / weight loss diet
A low-calorie Mediterranean diet combined with physical activity helps reduce age- and weight-related bone mineral density loss in older women with metabolic syndrome and obesity, offering a dual benefit for weight management and osteoporosis prevention.
Plant extracts may help treat metabolic syndrome
April 14, 2024 / plant extracts / metabolic syndrome therapy / phytochemicals insulin resistance / botanical supplements safety / natural diabetes treatment
Plant extracts may offer complementary benefits in managing metabolic syndrome by improving blood sugar, cholesterol, and inflammatory markers, but require further clinical validation for safety and effectiveness in diverse populations.
Rivus Pharmaceuticals Expands Leadership Team and Establishes New San Francisco Bay Area Office Ahead of Phase 2 Read-Out in MASH
April 10, 2025 / Rivus Pharmaceuticals / metabolic accelerator HU6 / MASH Phase 2b trial / obesity drug pipeline / cardiometabolic disease therapy
Rivus Pharmaceuticals expands its leadership and opens a new Bay Area office ahead of key Phase 2b MASH trial results for HU6, a Controlled Metabolic Accelerator targeting obesity and cardiometabolic diseases through fat-selective energy expenditure.
Northstrive partners with Yuva Biosciences on obesity and cardiometabolic diseases
April 11, 2025 / Northstrive Biosciences / Yuva Mitonova platform / mitochondrial science obesity / AI metabolic therapy / type 2 diabetes drug development
Northstrive Biosciences partners with Yuva Biosciences to develop obesity, type 2 diabetes, and cardiometabolic treatments using Yuva’s AI-driven mitochondrial platform, Mitonova, aiming to harness mitochondrial science for next-generation metabolic therapies.
Here’s how the season you were conceived in could change your metabolism
April 11, 2025 / brown fat metabolism / seasonal conception effects / epigenetics and obesity / metabolic health study / BMI and birth season
A Japanese study suggests that conception during colder months may increase adult brown fat activity, potentially enhancing metabolism and reducing obesity risk through epigenetic adaptations—though the findings are observational and not definitive.
Teladoc Health Launches New Cardiometabolic Health Program
April 9, 2025 / cardiometabolic health program / virtual obesity care / Teladoc diabetes prevention / sleep and metabolic health / lifestyle chronic disease management
Teladoc Health launched a new Cardiometabolic Health Program offering personalized virtual support—including dietitian coaching, at-home testing, and sleep therapy—to address obesity, diabetes, and hypertension, aiming to improve upstream risk factors and overall cardiometabolic health.
Dual-action nanoparticle therapy targets obesity by converting white fat and reducing inflammation
April 9, 2024 / nanoparticle obesity therapy / apigenin fat browning / immunomodulation metabolic disease / targeted adipose treatment / anti-inflammatory obesity treatment
Researchers developed apigenin-loaded nanoparticles that target adipose tissue to convert white fat to beige fat and reduce inflammation, offering a dual-action, immunomodulatory approach to treat obesity by addressing both metabolic dysfunction and chronic inflammation.
Unexpected lipid drop in obesity could lead to new therapies
April 8, 2025 / ceramides obesity cardiovascular / endothelial lipid regulation / obesity inflammation therapy / vascular health diabetes / ceramide lipid research
A Weill Cornell study found that reduced ceramide levels in endothelial cells—not their accumulation—may drive cardiovascular risks in obesity, suggesting therapies that sustain ceramide levels could protect vascular health in obese and diabetic patients.
Vision transformer based interpretable metabolic syndrome classification using retinal Images
April 11, 2025 / retinal image metabolic syndrome / AI health screening / vision transformer obesity / non-invasive metabolic diagnosis / retinal biomarkers cardiometabolic
Researchers developed a vision transformer model using retinal images to classify metabolic syndrome, achieving high accuracy, especially when combined with clinical data. Visualization techniques improved interpretability, highlighting retinal biomarkers as potential non-invasive indicators of metabolic health.
How Lactating Brains Rewire Metabolism for Milk Production
April 14, 2025 / lactation metabolism brain / estrogen prolactin appetite / hypothalamic neuron fat storage / maternal energy balance / obesity menopause prolactin
Lactation alters maternal metabolism by increasing prolactin and reducing estrogen, which suppresses estrogen receptor α neurons in the hypothalamus—boosting appetite and conserving fat. This adaptive brain-hormone mechanism may inform future treatments for obesity, menopause, and hyperprolactinemia.
GLP-1 agonists linked to lower risk of complications in MASLD, MASH
April 14, 2025 / GLP-1 agonists MASLD / fatty liver disease treatment / MASH cardiovascular risk / Ozempic liver outcomes / metabolic liver disease therapy
GLP-1 receptor agonists significantly reduced the risk of heart failure, liver complications, and all-cause mortality in patients with MASLD or MASH over seven years, highlighting their potential as therapeutic agents in fatty liver disease management.
Identifying a new target for metabolic liver disease treatment
April 10, 2025 / PTPRD liver metabolism / STAT3 metabolic disease / MASLD MASH treatment / insulin resistance obesity / peroxisomal dysfunction liver
Researchers have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism and insulin sensitivity. Its deficiency contributes to STAT3 overactivation, peroxisomal dysfunction, and metabolic liver disease, positioning PTPRD as a novel therapeutic and diagnostic target.
MASH Market Momentum: Late-Stage Assets Fuel Competitive Therapeutic Landscape
April 11, 2025 / ‘MASH treatment pipeline / FGF21 analogs liver / GLP-1 MASH therapies / AI in liver disease / late-stage NASH trials
MASH, a progressive liver disease with rising global impact, is driving intense R&D activity. Several late-stage therapies, including GLP-1 and FGF21 analogs, are in development, and AI tools like AIM-NASH are enhancing clinical trial precision.
Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment
April 8, 2025 / TWYMEEG approval Japan / Imeglimin renal impairment / type 2 diabetes treatment / mitochondrial diabetes drug / Poxel Sumitomo partnership
Japan’s PMDA has approved expanding TWYMEEG® (Imeglimin) labeling to include type 2 diabetes patients with moderate to severe renal impairment. Backed by Phase 4 TWINKLE study data, this move enhances treatment options and commercial potential in Asia.
Impact of High-Fat Diet-induced Metabolic Dysfunction-associated Steatotic Liver Disease on Heart, Kidney, and Skeletal Muscle Metabolomes in Wild-Type Mice
April 13, 2025 / MASLD mouse model / high-fat diet metabolism / kidney lipid metabolism / choline pathway disruption / metabolic liver disease biomarkers
A high-fat diet inducing MASLD in mice significantly alters metabolomes of the kidney, heart, and skeletal muscle, with the kidney showing the most metabolic disruption. Key changes suggest increased tissue stress, altered lipid metabolism, and impaired choline pathways.
Weight-loss lifestyle changes slow bone loss in older adults
April 14, 2025 / osteoporosis prevention / Mediterranean diet bone health / aging and BMD / metabolic syndrome lifestyle / weight loss and bone density
A Mediterranean diet with reduced calories and added physical activity significantly slowed age-related bone loss in older adults with metabolic syndrome, especially in women, improving bone mineral density (BMD) and reducing osteoporosis risk over three years.